Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sartorius Aktiengesellschaft (0NIR.L)

LSE - LSE Delayed Price. Currency in EUR
Add to watchlist
403.50+20.75 (+5.42%)
At close: 06:20PM BST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close382.75
Open388.30
BidN/A x N/A
AskN/A x N/A
Day's Range388.30 - 405.10
52 Week Range388.30 - 405.10
Volume8,951
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0NIR.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Sartorius to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions

      The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral thera

    • PR Newswire

      Resolutions of the Annual General Shareholders' Meeting of Sartorius AG

      At today's virtual Annual General Shareholders' Meeting, the shareholders of Sartorius AG granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority. They passed the resolution to pay dividends of 1,26 euros per preference share and 1.25 euros per ordinary share. The total amount disbursed will be 85.9 million euros. In the previous year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share.

    • PR Newswire

      Sartorius Annual General Shareholders' Meeting: Focus on innovation, growth and sustainability

      On the occasion of its virtual Annual General Shareholders' Meeting today, life science company Sartorius takes a positive look back at the past year and provides shareholders with details on further growth prospects. "Life sciences and the biopharmaceutical industry are currently in a very dynamic and innovative phase. Significant progress is being made at an increasing pace in the development of advanced therapies, such as cell and gene therapy methods, and mRNA technology is showing great pot

    Advertisement
    Advertisement